In a recent market study, Fact.MR covers recent developments in the global ornithine transcarbamylase deficiency treatment market, highlighting vital aspects such as trends, drivers, opportunities, and restraints.
Oral OTC Deficiency Medicine Delivery to Dominate the Ornithine Transcarbamylase Deficiency Treatment Market Share
In a recent market study, Fact.MR covers recent developments in the global ornithine transcarbamylase deficiency treatment market, highlighting vital aspects such as trends, drivers, opportunities, and restraints. The report studies recent developments in the segments of the market in terms of product, route of administration, distribution channel and by region.
Fact.MR – A Market Research and Competitive Intelligence Provider: Since a few years, genetic problems have been increasingly common. Urea cycle disorders (UCDs) and ornithine transcarbamylase (OTC) deficiency are two of the most common genetic abnormalities known to humanity.
The global ornithine transcarbamylase (OTC) deficiency treatment market is expected to expand steadily over the coming years and reach US$ 900 Mn by 2030. It is attributed to rising pervasiveness of this deficiency across world
OTC deficiency is inherited as an X-linked recessive trait, with males being more afflicted than females. OTC deficiency is predicted to affect 1 out of every 14,000 to 77,000 people. As a result, healthcare providers have increased their R&D capabilities in order to find viable solutions.
Rising prevalence of urea cycle disorders (UCDs) evoked to develop effective OTC deficiency treatments. Waste removal mechanism are affected by UCD, a genetically inherited disease.
For Critical Insights On This Market, Request For More Info
https://www.factmr.com/connectus/sample?flag=S&rep_id=5204
Patients are impaired with UCDs lack the catalytic enzyme required to convert excessive nitrogen into urea. This causes excessive ammonia deposition. This kind of ammonia deposition is highly toxic to the human body. Against this backdrop, various pharmaceutical companies are investigating possible novel approaches to address this disorder that helps in expansion of the ornithine transcarbamylase deficiency treatment market size.
Years of clinical trials and research in the medical community have led to gene therapy as a potential cure or prevention for OTC deficiencies all over the world. The goal of gene therapy is to give you a healthy copy of the OTC gene.
Manufacturers of BUPHENYL®, a line of sodium phenyl butyrate-based tablets and powders for oral administration, are expanding their production capabilities in the OTC deficient therapy market. The medication is currently being used as an adjuvant therapy to treat OTC deficiency.
“Conferment of orphan drug status by regulatory bodies is motivating manufacturers to accelerate development of novel OTC deficiency treatment formulations,” infers a Fact.MR analyst.
Key Takeaways:
- By product type, Ravicti-based OCT deficiency treatment drugs are predicted to be the most promising by the end of the forecast period, grabbing a sizable market share.
- The buphenyl sector is predicted to be the second most popular OTC deficiency drug category during the projection period.
- Oral OTC deficiency medicine delivery is expected to stay dominating during the projection period, with a significant CAGR.
- By distribution channel, hospital pharmacy segment is likely to create white spaces for the ornithine transcarbamylase deficiency therapy market in terms of distribution channel.
- Due to increased awareness of ornithine transcarbamylase deficiency, the Asia Pacific ornithine transcarbamylase deficiency therapy market is expected to grow at a faster CAGR over the forecast period.
Growth drivers:
- Pharmaceutical companies are investigating novel approaches to cure this disorder, this rises the expansion of the ornithine transcarbamylase deficiency treatment market size.
- The global market for ornithine transcarbamylase (OTC) deficiency treatment is expected to grow gradually over the next decade, owing to the increasing frequency of this deficiency among the world’s population.
To learn more about Ornithine Transacrbamylase Deficiency Treatment Market, you can get in touch with our Analyst at
https://www.factmr.com/connectus/sample?flag=AE&rep_id=5204
Competitive Landscape:
Product launches, acquisitions, and strategic collaborations form a part and parcel of the aforementioned market players’ key consolidation strategies.
- In February 2010, Abbott Laboratories acquired Solvay S.A for US$ 6.2 billion. This expanded the company’s pharmaceutical products portfolio and presence in key emerging markets.
- In 2017, Mead Johnson Nutrition merged with Reckitt Benckiser giving the company access to a much larger consumer base and allowing it to promote its nutrition-enhancing products on a much greater scale. Enfamil®, Enfagrow®, and Choco Milk® are just a few of the company’s offerings.
- Arcturus Technologies is developing a number of over-the-counter (OTC) deficiency therapy medications. It presently sells Messenger RNA (mRNA) infused medicines based on the LUNAR® delivery system to treat protein deficient illnesses like UCDs.
Key Players in the Ornithine Transacrbamylase Deficiency Treatment Market Include:
- Abbott Laboratories
- Solvay S.A
More Valuable Insights on Ornithine Transacrbamylase Deficiency Treatment Market
Fact.MR provides an unbiased analysis of the Ornithine transacrbamylase deficiency treatment market, presenting forecast statistics for the period from 2022-2032. The study divulges compelling insights on the Ornithine transacrbamylase deficiency treatment market with a detailed segmentation on the basis of:
Product
- Buphenyl
- Ravicti
- Ammonul
- Dietary Supplements
- Others
Route of Administration
- Oral
- Intravenous
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Explore Fact.MR’s Coverage on the Healthcare Domain –
Immunoglobulins Market Analysis - The global immunoglobulins market is expected to grow rapidly, owing to an increase in the prevalence of autoimmune illnesses. Immunoglobulins are being used more frequently for off-label indications, and this trend is expected to continue.
Cancer Therapeutics Market Forecast - Discoveries of revolutionary peptide-based medications are projected to influence developing trends in the cancer therapeutics market, with the cancer therapeutics sector is steady in its R&D operations. In the future years, peptide-based drugs are projected to become more widely used in cancer therapeutics.
Cancer Biomarkers Market Analysis - Governments’ aggressive funding initiatives for cancer diagnostics are expanding the market for cancer biomarkers. Demand for cancer biomarkers will be bolstered by factors such as the availability of low-cost, non-invasive prognosis.
Cancer Profiling Market Scope - The global cancer profiling market is predicted to grow significantly between now and 2021, as the demand for precision medicine and high-quality oncology care grows.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR